ArticleAmerican journal of nephrology2026
Factors Associated with Hyperkalemia in Chronic Kidney Disease: Insights from a Cohort with Measured Glomerular Filtration Rate.
Article in American journal of nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionHyperkalemia is a life-threatening disorder in chronic kidney disease (CKD), yet the contribution of key factors including age, sex, body mass index, and proteinuria remain controversial. We aimed to identify factors associated with chronic hyperkalemia in a large cohort of patients with gold-standard measured glomerular filtration rate (GFR) and standardized plasma potassium measurements.
methodsThis cross-sectional study of 5,046 adults with non-dialysis CKD referred for kidney workup, including radio-isotopic measured GFR, defined hyperkalemia as a plasma potassium concentration ≥5.0 mmol/L or the use of potassium binders. We analyzed demographic, clinical, pharmacological, and biochemical risk factors for hyperkalemia using logistic regression models.
resultsMean measured GFR was 59 ± 26 mL/min/1.73 m2, mean age was 52 ± 15 years, 42% were women, 22% were of sub-Saharan African ancestry, 25% had diabetes, and 36% were kidney transplant recipients. The prevalence of hyperkalemia was 6.4% and increased with declining measured GFR, from 1% in CKD stages 1-2-8% in CKD stage 3 and 21% in stages 4-5. In the multivariable model, measured GFR remained strongly associated with hyperkalemia (OR 1.65 [1.51-1.81] per 10 mL/min/1.73 m2 decrease), an effect amplified in renin-angiotensin-aldosterone system inhibitor (RAASi) users (1.82 [1.61-2.07]) (p for interaction 0.036). Other independently associated factors were diabetes (OR 1.67 [1.38-2.17]), RAASi and calcineurin inhibitor (OR 2.30 [1.72-3.11] and 1.39 [1.06-1.83] respectively), higher urinary albumin-to-creatinine ratio, and lower venous bicarbonate level, whereas female sex (OR 0.71 [0.55-0.92]), sub-Saharan African ancestry (HR 0.68 [0.48-0.94]), and loop diuretics (OR 0.71 [0.51-0.98]) were protective, and age and body mass index showed no independent association.
conclusionIn this large cohort, across the entire range of gold-standard measured GFR, hyperkalemia is driven primarily by reduced kidney function, diabetes, and RAASi, whereas protective factors were female sex, sub-Saharan African ancestry, and loop diuretic therapy. These robust findings, based on unbiased GFR assessment, identify key contributors for individualized prevention of hyperkalemia in CKD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.